MedPath

Cervical Preparation Before Dilation and Evacuation

Not Applicable
Completed
Conditions
Abortion, Induced
Interventions
Device: Osmotic dilators
Other: Mifepristone
Other: placebo
Registration Number
NCT01751087
Lead Sponsor
Planned Parenthood League of Massachusetts
Brief Summary

The purpose of this research study is to compare three different ways of opening a woman's cervix before her second-trimester surgical abortion.

* Osmotic dilators: small rods that, when inserted into the cervix, gently expand to open the cervix

* Osmotic dilators plus mifepristone, a medicine that is swallowed

* Osmotic dilators plus misoprostol, a medicine that is placed between the cheek and gum

Hypotheses:

* adding buccal misoprostol 3 hours preoperatively will significantly improve dilation compared to laminaria alone, making procedures faster, easier and safer.

* adding oral mifepristone at the time of laminaria placement will confer a similar benefit.

* the efficacy of adjunctive misoprostol and mifepristone will be influenced by gestational age, with women later in gestation having increased efficacy from these agents.

* significantly more patients who receive adjunctive misoprostol or mifepristone will have adequate initial dilation, fewer will require manual dilation or additional cervical preparation and there will be fewer complications in these arms, although complication rates will be low and we will only be able to detect relatively large differences.

* patients will prefer to have the procedure done as quickly as possible with as little discomfort as possible, that cervical ripening with adjunctive misoprostol will be associated with more cramping than osmotic dilators alone and that mifepristone will be well tolerated and may not cause more cramping or other side effects than osmotic dilators alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
300
Inclusion Criteria
  • 18 years and older
  • Able to give informed consent
  • Medically eligible for outpatient second trimester pregnancy termination at the clinical site
  • English-speaking or Spanish-speaking at sites with ability to obtain informed consent in Spanish
Exclusion Criteria
  • Active bleeding (>1 pad/hour) or hemodynamically unstable at enrollment
  • Signs of chorioamnionitis or clinical infection at enrollment
  • Signs of spontaneous labor or cervical insufficiency at enrollment
  • Spontaneous intrauterine fetal demise
  • Patient incarcerated
  • Allergy to mifepristone or misoprostol
  • Chronic steroid use or adrenal insufficiency
  • Porphyria
  • Inflammatory bowel disease requiring treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Osmotic dilators + placebo (vit c) + placebo (vit B12)placeboWomen will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators + placebo (vit c) + placebo (vit B12)Osmotic dilatorsWomen will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
Osmotic dilators + mifepristone + placebo (vit B12)MifepristoneWomen will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Osmotic dilators + placebo (vit c) + misoprostolOsmotic dilatorsWomen will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
Osmotic dilators + mifepristone + placebo (vit B12)placeboWomen will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Osmotic dilators + placebo (vit c) + misoprostolplaceboWomen will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
Osmotic dilators + mifepristone + placebo (vit B12)Osmotic dilatorsWomen will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
Osmotic dilators + placebo (vit c) + misoprostolmisoprostolWomen will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
Primary Outcome Measures
NameTimeMethod
Operative Timeparticipants were assessed for the duration of the procedure, an average of 6 minutes

The duration of the D\&E procedure was measured with a stopwatch, starting with the first instrument that passes into the uterus and ending when the last instrument is removed from the uterus upon completion of the D\&E

Secondary Outcome Measures
NameTimeMethod
Initial Cervical Dilationparticipants were assessed during cervical dilation process, average time of 1 minute

Measured at the time of procedure (immediately before the start of D\&E)

Need for Mechanical Dilationparticipants were assessed for the duration of the procedure, an average of 6 minutes

Assessed on Day of procedure. Assessed immediately after completion of D\&E

Ease of Mechanical Dilationparticipants were assessed for the duration of the procedure, an average of 6 minutes

Number of participants for whom, if additional mechanical dilation was required, it was difficult or very difficult. Assessed on day of procedure. Assessed after completion of D\&E

Complications From Procedureassessed immediately after completion of D&E and at 1 week and 1 month post-procedure

Patient having any complication, including hospitalizations transfusions additional unplanned procedures

Ability to Complete the D&E on the First Attemptparticipants were assessed for the duration of the procedure, an average of 6 minutes

Assessed on day of procedure and following day. If the procedure was unable to be completed as planned and the subject had to leave the procedure room and return for another attempt either at a time later the same day or the next day.

Chills (Any) After Day 2 Medication Administrationassessed immediately after administration of day 2 medication

chills (any) after Day 2 medication administration

Physician Satisfaction With Cervical Preparationphysicians' satisfaction with cervical prep was evaluated over course of procedure, an average of 6 minutes

Participants for whom the operating physician reported being satisfied or very satisfied with the cervical preparation. Assessed on Day of procedure. Assessed after completion of D\&E procedure.

Patient Satisfaction With Cervical Preppatients' satisfaction with cervical prep was evaluated over course of cervical prep and procedure, up to 3 days

Patients who were very satisfied or satisfied with cervical preparation. Assessed on Day of procedure. Assessed after completion of D\&E procedure and just prior to discharge home.

Trial Locations

Locations (7)

Family Planning Associates

🇺🇸

Chicago, Illinois, United States

Planned Parenthood of New York City

🇺🇸

New York, New York, United States

Lovejoy Surgical Center

🇺🇸

Portland, Oregon, United States

Magee Women's Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

San Francisco General Hospital

🇺🇸

San Francisco, California, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath